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Abstract
Background: CXCL12 has been widely reported to play a biologically relevant role in tumor growth and spread. In
epithelial ovarian cancer (EOC), CXCL12 enhances tumor angiogenesis and contributes to the immunosuppressive
network. However, its prognostic significance remains unclear. We thus compared CXCL12 status in healthy and
malignant ovaries, to assess its prognostic value.
Methods: Immunohistochemistry was used to analyze CXCL12 expression in the reproductive tracts, including the
ovaries and fallopian tubes, of healthy women, in benign and borderline epithelial tumors, and in a series of 183
tumor specimens from patients with advanced primary EOC enrolled in a multicenter prospective clinical trial of
paclitaxel/carboplatin/gemcitabine-based chemotherapy (GINECO study). Univariate COX model analysis was
performed to assess the prognostic value of clinical and biological variables. Kaplan-Meier methods were used to
generate progression-free and overall survival curves.
Results: Epithelial cells from the surface of the ovary and the fallopian tubes stained positive for CXCL12, whereas
the follicles within the ovary did not. Epithelial cells in benign, borderline and malignant tumors also expressed
CXCL12. In EOC specimens, CXCL12 immunoreactivity was observed mostly in epithelial tumor cells. The intensity
of the signal obtained ranged from strong in 86 cases (47%) to absent in 18 cases (<10%). This uneven distribution
of CXCL12 did not reflect the morphological heterogeneity of EOC. CXCL12 expression levels were not correlated
with any of the clinical parameters currently used to determine EOC prognosis or with HER2 status. They also had
no impact on progression-free or overall survival.
Conclusion: Our findings highlight the previously unappreciated constitutive expression of CXCL12 on healthy
epithelia of the ovary surface and fallopian tubes, indicating that EOC may originate from either of these epithelia.
We reveal that CXCL12 production by malignant epithelial cells precedes tumorigenesis and we confirm in a large
cohort of patients with advanced EOC that CXCL12 expression level in EOC is not a valuable prognostic factor in
itself.
Trial Registration: ClinicalTrials.gov: NCT00052468
Background
Epithelial ovarian cancer (EOC) has one of the highest
mortality rates of all gynecologic malignancies. It is the
sixth most common cancer and the fifth most common
cause of cancer-related death among women in devel-
oped countries [1]. Due to the silent nature of early-
stage disease, most women with EOC have disseminated
disease (i.e. expansion in the peritoneum and metastasis
in the omentum) at the time of diagnosis and present
an advanced stage of the disease, with a five-year survi-
val rate below 30% [2]. Despite the high incidence and
mortality rates, the etiology of EOC and the molecular
pathways underlying its progression remain poorly
understood. According to the International Federation
of Gynecology and Obstetrics (FIGO), clinical stage, his-
tologic grade and postoperative residual tumor mass are
the most important prognostic factors in patients with
* Correspondence: veronique.machelon@u-psud.fr; karl.balabanian@u-psud.fr
1INSERM UMR_S 996, Université Paris-Sud 11, Clamart, 92140 France
Full list of author information is available at the end of the article
Machelon et al. BMC Cancer 2011, 11:97
http://www.biomedcentral.com/1471-2407/11/97
© 2011 Machelon et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
EOC [3]. However, clinical factors and derivative prog-
nostic models remain inadequate for the accurate pre-
diction of outcome for a specific patient, indicating a
need for the identification of biological factors to
improve prognostic assessment. This aspect has recently
been addressed with the identification of several biomar-
kers for the identification of histologic subtypes and the
more accurate prediction of patient outcome [4-9]. Che-
mokines and their receptors have been known for many
years to influence the development of primary epithelial
tumors, in which they regulate the proliferation and
survival of tumor cells, tumor-infiltrating leukocytes,
angiogenesis and metastasis [10-12]. In epithelial can-
cers, these molecules play a key role in controlling both
autocrine and paracrine communication between the
different cell types of the tumor microenvironment [13].
Thus, chemokines and their receptors may constitute
new biomarkers of potential prognostic value in various
cancers, including EOC.
In this study, we focused on the a-chemokine stromal
cell-derived factor-1 (SDF-1)/CXCL12, which, together
with its receptors CXCR4 and CXCR7, constitutes the
chemokine/receptor axis attracting the greatest level of
interest in oncology [11,14]. In EOC, CXCL12 products
(i.e. protein and mRNA) have been detected in tumor
cells [15,16]. We previously showed that CXCL12
orchestrates the recruitment of pre-DC2s and protects
them from tumor macrophage IL-10-promoted apopto-
sis, thereby contributing to the immunosuppressive net-
work within the tumor microenvironment [15]. In
addition, CXCL12 regulates tumor angiogenesis, a criti-
cal step in tumor growth. Indeed, we have shown that
hypoxia triggers the production of CXCL12 and vascular
endothelium growth factor (VEGF) by EOC, with these
two molecules acting in synergy to enhance tumor
angiogenesis in vivo [17]. CXCL12 also acts on tumor
cell proliferation and survival and, through its main
receptor CXCR4, governs the migration of malignant
cells and their invasion of the peritoneum, a major
route for ovarian cancer spread [16,18-20]. Other factors
must also been considered, but previous observations
strongly suggest that CXCL12 provides the autocrine
and paracrine signals controlling malignant progression
in EOC [11]. Some recent studies have investigated
CXCL12 status in EOC, and reported no prognostic sig-
nificance of CXCL12 production [11,21,22]. However,
the results were obtained with ovarian cancer specimens
from patients undergoing chemotherapy via heteroge-
neous protocols, with a follow-up period of less than
four years. The prognostic significance of CXCL12 pro-
duction by ovarian cancer cells remains to be clearly
assessed in larger cohorts of EOC patients undergoing
the same type of chemotherapy and followed up for
longer periods. Furthermore, the pattern of CXCL12
expression in healthy ovaries and in benign and border-
line ovarian tumors has scarcely been investigated. Elu-
cidation of these points is required to determine
whether CXCL12 production is associated with the
malignant process and whether it constitutes a valuable
prognostic factor in EOC.
In this study, we investigated CXCL12 status in the
reproductive tracts of healthy women. We studied the
ovarian surface epithelium (OSE) and fallopian tubes,
both of which are considered probable sources of EOC
[23,24]. We also investigated CXCL12 status in benign
and borderline epithelial tumors, and in a series of 183
patients with advanced primary EOC enrolled in a
multicenter prospective clinical trial of paclitaxel/car-
boplatin/gemcitabine (TCG)-based chemotherapy
[ClinicalTrials.gov Identifier: NCT00052468]. We
quantified CXCL12 by immunohistochemistry (IHC) in
EOC specimens and further assessed its potential asso-
ciation with clinical and pathologic features, including
staging parameters and tumor histotypes, and with the
expression of HER2, a tyrosine kinase receptor that
may influence outcome when overexpressed [21,25].
Finally, we investigated whether the production of
CXCL12 within the tumor affected progression-free
survival (PFS) and the overall survival (OS) of patients
with advanced primary EOC.
Methods
Ethics statement
We included 183 patients with advanced primary EOC
(FIGO stage Ic-IV) in this study. All had been enrolled
in the GERCOR-AGO-OVAR-9 large phase III rando-
mized trial of first-line TCG-based chemotherapy
(GINECO study) conducted at 58 French centers from
July 2002 to April 2004 [ClinicalTrials.gov Identifier:
NCT00052468] [25-27]. Formalin-fixed, paraffin-
embedded tumors from primary surgery were obtained
with the approval of the institutional review board of
the corresponding center (CCPPRB number: 02780)
after inclusion of the patient in the clinical trial. Forma-
lin-fixed and paraffin-embedded specimens recovered
from five healthy ovaries (mostly contralateral to the
malignant ovary), eight benign tumors (4 serous and 4
mucinous), eight borderline tumors (4 serous and 4
mucinous), and three non epithelial ovarian tumors (2
granulosa tumors and 1 dysgerminoma) were provided
from the archives of patients treated at Antoine-Béclère
Hospital (Service d’Anatomie et de Cytologie Pathologi-
ques, Clamart, France) between 1998 and 2007.
Approval was obtained from the ethics commission of
Antoine-Béclère Hospital for all analyses of tumor mate-
rial from the archives initially obtained for routine diag-
nostic and therapeutic purposes. This study was carried
out in accordance with good clinical practice guidelines,
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national laws, and the Declaration of Helsinki. All
patients provided written informed consent.
Cell enrichment
Tumor cell enrichment from malignant ascites was
based on the expression of CD326, a human epithelial
antigen also known as EpCAM, one of the most fre-
quently identified and highly expressed biomarkers in
EOC [28]. CD326+ cells were positively selected on
AutoMACs columns (Myltenyi Biotech, Paris, France),
from ascites samples collected with ethics committee
(Antoine-Béclère Hospital) approval from one patient
(FIGO stage IV) diagnosed with invasive EOC with peri-
toneal extension, as previously described [29]. In the
positive fraction, the percentage of CD326+ cells was
>80%, whereas the negative fraction contained mostly
CD45+ leukocytes, as determined by flow cytometry
(FACSCalibur, BD Biosciences, Le Pont De Claix,
France) with FITC-conjugated anti-human CD45 (clone
H130, IgG1, BD Biosciences) and PE-conjugated anti-
human CD326 (clone HEA 125, IgG1, Myltenyi Biotec)
monoclonal antibodies (mAb). Ascites samples were also
analyzed for CXCL12 content with the human CXCL12/
SDF-1a Quantikine ELISA kit (R&D Systems, Lille,
France), according to the manufacturer’s instructions.
Immunostaining grading and score
CXCL12 was localized immunohistochemically on 4 μm
sections of paraffin-embedded tissues (healthy ovaries,
benign, borderline and non epithelial tumors) and on
tissue microarrays (TMAs) of EOC specimens. Identical
experimental protocols were used for immunohisto-
chemistry (IHC) on conventional slides and TMAs. Sec-
tions were deparaffinized and rehydrated and then
treated with citrate buffer pH6 and heated in a micro-
wave oven. For CXCL12 immunostaining, we used a
mAb against CXCL12 (clone K15C, IgG2a) at a concen-
tration of 1.37 μg/ml. This mAb has already been widely
used for the detection of CXCL12 in mesothelial cells,
ovarian cancer cells and breast carcinomas [15,30-33].
The binding of the K15C mAb was detected by the
streptavidine-biotin peroxidase method (LSAB kit, Dako,
Trappes, France). Sections were then counterstained
with hematoxylin. Images were obtained with a Leica
DMLB microscope equipped with standard optic objec-
tives, at the indicated magnifications, and digitized
directly with a Sony 3CCD color video camera.
Immunostaining for CXCL12 was then scored by two
independent investigators (F.G. and S.C-B), as follows:
an intensity score of 0 if negative, 1 (weak intensity), 2
(moderate intensity) or 3 (strong intensity), added to a
score for the percentage of positive cells, of 0 (0%), 1 (1-
10%), 2 (10-50%), 3 (50-80%) or 4 (>80%), as recently
reported [29]. Tumor specimens scoring 0 to 4 were
considered to display low-moderate levels of CXCL12
expression (CXCL12low/moderate, n = 97), whereas those
scoring 5 to 7 were classified as having high levels of
CXCL12 expression (CXCL12high, n = 86). For the 183
patients included in the GINECO clinical trial, results
were compared with IHC for HER2, as previously
described [26].
RT-PCR analyses
Total cellular RNA was extracted from freshly frozen
ovarian tissue samples, with the RNeasy Mini kit (Qia-
gen, Courtaboeuf, France). It was then reverse-tran-
scribed with random hexamers (Roche Diagnostics,
Meylan, France) and Moloney murine leukemia virus
reverse transcriptase (Fisher Bioblock, Illkirch, France).
The resulting cDNAs (1 μg) were then amplified by
semi-quantitative PCR (2 min at 94°C followed by 33
cycles of 30 s at 61°C or 55°C for CXCL12 and b-actin,
respectively) with forward (658-677) 5’-GGGCTCCTGG
GTTTTGTATT-3’ and reverse (1056-1075) 5’-
GTCCTGAGAGTCCTTTTGCG-3’ primers for CXCL12
(417 bp), and forward (214-223) 5’-GGGTCAGAAG-
GATTCCTATG-3’ and reverse (432-451) 5’-GGTCTC
AAACATGATCTGGG-3’ primers for b-actin (237 bp).
Quantitative real-time PCR was performed on a Light
Cycler instrument (LC480, Roche Diagnostics) with the
LightCycler 480 SYBR Green detection kit (Roche Diag-
nostics) and forward (178-203) 5’-GTCAAGCATCT-
CAAAATTCTCAACAC-3’ and reverse (262-281) 5’-CA
CTTTAGCTTCGGGTCAATGC-3’ primers for CXCL12
(103 bp), and forward (214-223) 5’-GGGTCAGAAG-
GATTCCTATG-3’ and reverse (432-451) 5’-GGTCTCA
AACATGATCTGGG-3’ primers for b-actin (237 bp).
We used the ABI 7300 Sequence Detection System
(Applied Biosystems, Courtaboeuf, France) with the fol-
lowing amplification scheme: 95°C for 10 min and 45
cycles of 95°C for 10 s, 68°C for 10 s and 72°C for 5 s.
The dissociation curve method was applied, according
to the manufacturer’s protocol (60°C to 95°C), to ensure
the presence of a single specific PCR product. The stan-
dard curve method was used for analysis, and results are
expressed as CXCL12/b-actin ratios.
Statistical analyses
For the series of 183 patients included in the GINECO
clinical trial, the relationship between CXCL12 expres-
sion and clinical and pathologic features was assessed
with t-tests (continuous variables) or Fisher’s exact tests
(binary variables). Overall survival (OS) was calculated
from the date of inclusion to death and progression-free
survival (PFS) was calculated from the date of inclusion
until progression or last follow-up examination. Progres-
sion was defined as a 20% increase in the diameter of all
measured lesions, the appearance of new lesions and/or
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the doubling of CA125 tumor marker concentration
from baseline values. Kaplan-Meier analysis was carried
out to generate PFS and OS curves. Univariate COX
model analysis was carried out to assess the prognostic
influence of clinical and biological variables. Hazard
ratios (HR) and 95% confidence intervals (CIs) were
determined. Analyses were performed with R software
(The R Foundation for Statistical Computing ISBN 3-
900051-07-0, http://www.r-project.org). For comparisons
of CXCL12 mRNA levels in EOC samples, we used
unpaired two-tailed Student’s t tests (Prism software,
GraphPad). P values <0.05 were considered statistically
significant.
Results
Detection of CXCL12 products in healthy and malignant
ovarian epithelial cells
The cellular expression of CXCL12 was examined by
IHC on sections isolated from five healthy ovaries, eight
serous or mucinous benign tumors (some still contain-
ing normal ovarian tissue), eight serous or mucinous
borderline epithelial tumors, three non epithelial ovarian
tumors (i.e. 2 granulosa tumors and 1 dysgerminoma),
and 183 invasive EOC. CXCL12 was clearly detected in
cells of the OSE and the fallopian tube epithelium (Fig-
ure 1A). By contrast, CXCL12 was absent from both
ovarian follicles and oocytes. CXCL12 immunoreactivity
was detected in epithelium-derived proliferating tumor
cells from benign tumors (Figure 1B). In both serous
and mucinous borderline tumors and in serous, clear-
cell, endometrioid and mucinous EOC specimens,
CXCL12 was heterogeneously distributed in malignant
cells, defining low and high expression profiles (Figures
1C and 1D). CXCL12 was confined to the cytoplasm of
malignant epithelial cells, with particularly strong stain-
ing of the membrane frequently observed, and was not
detected in nuclei (Figure 1D). CXCL12 was barely
detectable in the stroma, and tumor epithelial cells are
thus probably the principal source of CXCL12 in EOC.
Epithelial cells isolated from malignant ascites and iden-
tified as CD326+ cells were stained for CXCL12, whereas
their CD326- non epithelial counterparts, consisting
mostly of CD45+ leukocytes, were not stained for
CXCL12 (Figure 1E). CXCL12 was also absent from non
epithelial ovarian tumors (Figure 1F). A similar pattern
was observed for CXCL12 mRNA, as shown by conven-
tional and real-time PCR (Figure 2). CXCL12 was
assayed in the culture medium of three ovarian cancer
cell lines, SKOV-3, OVCAR-3 and BG-1, and in malig-
nant ascites. We found that CXCL12 was produced in
all cases, at concentrations of 2 to 10 ng/ml. Thus, the
epithelial cells of both the OSE and fallopian tubes con-
stitutively produce CXCL12 in the reproductive tracts of
healthy women. CXCL12 was recovered from benign,
borderline and malignant epithelial tumors but not from
non epithelial ovarian tumors.
Correlation of CXCL12 expression with clinical and
pathological characteristics
We evaluated the prognostic value of CXCL12 for EOC,
by quantifying CXCL12 staining in 183 ovarian cancer
specimens. The mean age of the patients at initial diag-
nosis was 59 years (range 25-77); 68% of patients had
serous adenocarcinomas and 85% had stage III/IV dis-
ease. Median follow-up for patients was 69 months.
CXCL12 was heterogeneously distributed in tumor cells,
with some cells displaying no detectable staining and
others, strong immunoreactivity. CXCL12 expression
ranged from high levels (scores 5-7) in 86 (47%) speci-
mens to an absence of staining in 18 (<10%) cases. We
applied a single cut-off at score 4, the median and mean
value of the entire cohort, for the identification of sam-
ples producing low-moderate (CXCL12low/moderate,
scores 0-4, n = 97) and high (CXCL12high, scores 5-7, n
= 86) levels of CXCL12. The median age of the patients
was 59 (range 25-77) in the CXCL12low/moderate group
and 57 (range 33-75) in the CXCL12high group. There
was thus no significant difference in patient age between
these two groups (P = 0.31). Statistical analyses of
CXCL12high and CXCL12low/moderate immunostaining
and classical clinical parameters, such as histotype,
HER2 status, FIGO stage, ascites and size of residual
tumor after first laparotomy, revealed no significant cor-
relation of CXCL12 status with any of the parameters
tested (Table 1). Thus, CXCL12 expression does not
reflect the clinical status of OEC.
Correlation of CXCL12 expression and patient outcome
We then investigated whether CXCL12high or
CXCL12low/moderate status affected OS and/or PFS. As
expected, univariate analysis validated, for this series,
known prognosis factors such as performance status,
FIGO stage, presence of ascites and residual tumor after
first laparotomy, which were associated with shorter OS
and PFS (Table 2). In our large and homogeneous
cohort, CXCL12 expression levels had no effect on OS
or PFS (Table 2 and Figure 3). Thus, CXCL12 expres-
sion by tumor epithelial cells is not in itself a valuable
prognostic factor in patients with advanced EOC.
Discussion
In this study, we demonstrate the previously unappre-
ciated constitutive expression of CXCL12 by healthy
ovarian epithelial cells and ovarian epithelial tumor
cells, whether benign or malignant. CXCL12 was recov-
ered from both the OSE and the epithelium of the fallo-
pian tubes, both of which are considered possible
origins of EOC. By contrast, it was not detected in
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follicles and oocytes or in malignant tumor cells arising
from them, granulosa tumors or dysgerminomas.
Furthermore, CXCL12 expression correlated neither
with clinical parameters nor with HER2 status in speci-
mens from 183 patients with advanced primary EOC
enrolled in a multicenter clinical trial of first-line TCG-
based chemotherapy (GINECO study). The intratumoral
production of CXCL12 does not reflect the morphologi-
cal heterogeneity of EOC and has no impact on PFS or
OS after adjustment for established prognostic factors.
Thus, CXCL12 is expressed by ovarian epithelial cells
before tumorigenesis and does not constitute a valuable
prognostic factor in EOC patients.
Recent studies on the origin and histogenesis of EOC
have proposed that type I tumors, which are believed to
include all major histotypes, originate from the OSE,
whereas type II tumors, which are thought to consist
almost exclusively of high-grade serous carcinomas,
arise from the distal region of fallopian tubes [4,24,34].
Our findings clearly demonstrate that CXCL12 is
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Figure 1 CXCL12 expression in healthy and malignant ovaries. (A) Healthy ovary (i), CXCL12 immunoreactivity in OSE (inset is the outlined
region on the tissue specimen containing surface epithelium, × 40), faint staining in the stroma and no signal in follicles and oocytes (arrow) (×
20); fallopian tube (ii), CXCL12 immunoreactivity in cells of the epithelium (× 40). (B) Serous (i) and mucinous (ii) benign epithelial ovarian
tumors, CXCL12 immunoreactivity in proliferating epithelial cells (× 40). (C) Serous (i and iii) and mucinous (ii and iv) borderline epithelial ovarian
tumors with low (CXCL12low, i and ii) or high (CXCL12high, iii and iv) levels of CXCL12 staining (× 40). (D) Malignant epithelial ovarian tumors:
serous (i), mucinous (ii), clear-cell (iii) and endometrioid (iv), CXCL12 immunoreactivity in epithelial cells is confined to the cytoplasm, with
frequent strong staining of the membrane (arrows), no staining in the nuclei of tumor cells or in the stroma (× 40). (E) Cytocentrifuged CD326+
epithelial (i) and CD326- non epithelial (ii) cells isolated from malignant ascites collected from a patient diagnosed with invasive EOC, CXCL12 is
detected only in CD326+ cells (× 40). (F) Non epithelial ovarian tumors: granulosa tumor (i) and dysgerminoma with characteristic morphological
features, i.e. Exner bodies (arrow) (ii), absence of CXCL12 immunostaining from both tumors (× 40). No labeling was detected when the K15C
anti-CXCL12 mAb was omitted or a 100-fold molar excess of recombinant CXCL12 was added to the mAb before incubation with tissues.
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constitutively produced by the epithelial cells of the
OSE, whereas such expression was not previously sus-
pected [11,16]. This apparent discrepancy may result
from differences between our experimental protocol and
those used in previous studies. For example, we used an
anti-CXCL12 mAb rather than a polyclonal Ab and an
additional microwave pretreatment for antigen retrieval,
both of which would have increased the sensitivity of
immunostaining. CXCL12 was also recovered from the
epithelial cells of fallopian tubes, which were recently
identified as a possible origin of high-grade serous EOC
and which have a Müllerian duct-derived embryologic
origin in common with the OSE [23,28,35]. By contrast,
CXCL12 was undetectable in follicles, oocytes and their
malignant non epithelial counterparts. Thus, CXCL12 is
a chemokine constitutively produced by epithelial ovar-
ian cells, from both healthy and malignant tissues.
CXCL12 is present in ovarian epithelial cells before they
become malignant and is therefore not useful as a mar-
ker of malignancy in EOC.
Scotton and coworkers reported a trend toward stron-
ger CXCL12 expression in higher grade tumors [16].
However, Pils and coworkers recently found that the
abundance of CXCL12 did not differ between borderline
and malignant tumors [21]. In the present work,
CXCL12 expression was detected in benign tumors as
well as in borderline and malignant tumors. Although
CXCL12 is unevenly distributed in low-grade (i.e. bor-
derline and stage I) and in more advanced stage tumors,
we have no evidence that its expression level is weaker
in low-grade tumors. Among CXCL12-positive EOC
specimens, we observed no significant differences in the
fraction of CXCL12high-producing tumors for the four
histotypes examined (i.e. serous, clear-cell, endometrioid
and mucinous), despite previous reports of differences
in epidemiologic and genetic changes, tumor markers
and response to treatment (reviewed in [11]). We sug-
gest that CXCL12 production levels overlap with EOC
histotype differentiation and staging. Consistent with
previous findings [16,22], CXCL12 was detected in more
than 90% of patients with advanced primary EOC. How-
ever, it was barely detectable in the remaining cases
(<10%), suggesting that CXCL12 expression might have
been silenced, possibly through epigenetic mechanisms,
such as promoter hypermethylation, a phenomenon
already reported for colon carcinoma and breast cancer
[36,37]. Indeed, further in-depth studies are required to
determine whether transcriptional regulatory mechan-
isms account for heterogeneous CXCL12 production in
EOC.
Recent studies have assessed the prognostic signifi-
cance of CXCL12 expression in various cancers, includ-
ing colorectal carcinoma [38], pancreatic ductal
adenocarcinoma [39], breast cancer [40], esophageal
squamous cell carcinoma [41], endometrial cancer [42],
germ cell tumors [43] and EOC [21,22]. The study
reported here was based on a large, homogeneous
cohort of 183 patients, all given standard TCG-based
chemotherapy. IHC showed that CXCL12 abundance
was not correlated with any of the clinical parameters
tested or with the HER2 status. Patients with
CXCL12high-producing tumors had a PFS and OS simi-
lar to those of patients with CXCL12low/moderate-produ-
cing tumors. Consistent with the findings of smaller
cohorts of patients given heterogeneous treatments
[21,22], we therefore suggest that there is no evidence
that CXCL12 production by malignant epithelial ovarian
cells is of prognostic significance in EOC.
This lack of prognostic value for CXCL12 in EOC is
somewhat puzzling, as this chemokine has been
reported to enhance tumor cell proliferation and
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Figure 2 Steady-state levels of CXCL12 transcripts in healthy
and malignant ovarian tissues. (A) CXCL12 mRNA was detected
by conventional PCR and was of the expected size (417 bp) in
healthy ovaries (faint signal), benign and invasive ovarian tumors
(strong signal) and in CD326+ epithelial cell-enriched malignant
ascites samples. By contrast, CXCL12 transcripts were absent from
CD326- non epithelial cells. The results presented are from one
experiment representative of three carried out. The white vertical
line separates lanes not run on the same gel. (B) CXCL12 mRNA
levels were quantified by real-time PCR and are expressed as
CXCL12/b-actin ratios. The diagram shows the distribution of values
and means for EOC samples identified as CXCL12high and
CXCL12low/moderate. Each symbol represents an individual sample run
in duplicate. The P value presented is that for a two-tailed Student’s
t test.
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survival [16,18-20,44], to promote angiogenesis [17], to
inhibit the host immune response [15] and to mediate
resistance to hyperthermic intraperitoneal chemotherapy
[45], which may favor tumor growth and spread. This
apparent paradox may be explained by the cellular
expression of CXCL12 not providing a true reflection of
its bioavailability, which depends principally on the pre-
sence in the tumor microenvironment of factors capable
of disrupting CXCL12 from glycosaminoglycans [46].
Moreover, CXCL12 activity may be mediated by two
receptors, CXCR4 and CXCR7, and these receptors may
also be rate-limiting elements. For many years, CXCL12
and CXCR4 were thought to act as an exclusive non
redundant pair. However, the recent identification of
RDC1/CXCR7 as a second receptor for CXCL12 has
challenged this view, and we now need to determine the
respective contributions of CXCR4 and CXCR7 to the
homeostatic and pathological activities of CXCL12
Table 1 Correlation of CXCL12 expression with clinical parameters
Patient number P valuea
CXCL12low/moderate CXCL12high
Scores (0-4) Scores (5-7)
Histotype
Serous (n = 125) 66 59 0.90 (NS)
Non serous (n = 58) 31 27
HER2
Negative (n = 171) 93 78 0.57 (NS)
Positive (n = 10) 4 6
Undetermined (n = 2)
FIGO stage
I+II (n = 27) 14 13 0.91 (NS)
III+IV (n = 155) 82 73
Undetermined (n = 1)
Ascites
Absence (n = 74) 37 37 0.45 (NS)
Presence (n = 86) 47 39
Undetermined (n = 23)
Residual tumor after initial laparatomy
>1 cm (n = 83) 40 43 0.98 (NS)
≤1 cm (n = 24) 11 13
Undetermined (n = 76)
aFisher’s exact test. NS: not significant.
Table 2 Hazard ratios for OS and PFS of 183 patients with EOC after univariate COX regression analysis of CXCL12
abundance and clinical and pathologic features
Overall survival Progression-free survival
HRa [95% CIb] P value HR [95% CI] P value
CXCL12 (5-7)
vs (0-4)
0.80 [0.51-1.28] 0.36 0.91 [0.65-1.29] 0.62
HER2
Positive vs negative
1.41 [0.68-2.90] 0.36 1.45 [0.84-2.51] 0.18
Age
>60 vs ≤60 years
1.40 [0.99-1.97] <0.057 1.17 [0.90-1.51] 0.22
Performance status
1+2 vs 0
1.72 [1.20-2.48] <0.003 1.45 [1.11-1.88] <0.005
FIGO stage
III+IV vs I+II
5.55 [2.27-13.60] <0.0002 4.43 [2.65-7.39] <0.0001
Ascites
Presence vs absence
3.33 [2.16-5.14] <0.0001 2.29 [1.71-3.05] <0.0001
Residual tumor after initial laparotomy
>1 cm vs ≤1 cm
1.72 [1.03-2.88] <0.04 1.97 [1.36-2.87] <0.0004
aHazard ratio. b95% confidence interval.
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[47-49]. The emerging possibility that CXCR7 acts as a
decoy receptor provides further support for a potential
role in EOC. Finally, the lack of influence of CXCL12
may reflect the unusual characteristics of metastases,
predicting the occurrence of which is one of the major
challenges in efforts to improve the clinical outcome of
EOC. By contrast to breast cancer, in which distant
metastases to the liver, lung and bone marrow are
favored by high levels of CXCL12 expression in target
organs and lower levels within the tumor [50], EOC
spreads by the direct seeding of tumor cells into the
peritoneal cavity, with preferential metastasis to local
lymph nodes. In EOC, CXCL12 mRNA and protein
have been detected mostly in the tumor cells them-
selves, and this feature has been reported for other can-
cers, including follicular lymphoma, pancreatic cancer,
glioma and astrocytoma [10]. Ovarian epithelial tumor
cells constitute a potent source of CXCL12. CXCL12
may therefore retain tumor cells at the site of produc-
tion, rather than encouraging them to disseminate and
to form secondary tumors in organs at some distance
from the original tumor.
Conclusions
Our findings highlight the previously unappreciated con-
stitutive expression of CXCL12 by healthy epithelia of
the ovary surface and the fallopian tubes, both these
epithelia having been identified as probably sources of
EOC. Thus, CXCL12 is expressed by epithelial cells
before they become malignant. We also show that the
level of CXCL12 expression in cancer cells is not a valu-
able prognostic factor in patients with advanced EOC.
These findings do not exclude the possibility that
CXCL12 contributes to tumor growth and spread via
autocrine and/or paracrine action. There is therefore a
need to determine whether CXCL12 status in EOC
depends on its bioavailability and on the CXCR4/
CXCR7 ratio in tumor cells, which would support an
effect of CXCL12.
List of abbreviations used
CI: Confidence interval; EOC: Epithelial ovarian cancer; FIGO: International
Federation of Gynecology and Obstetrics; HR: Hazard ratio; IHC:
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PFS: Progression-free survival; SDF-1: Stromal cell-derived factor-1; TCG:
Figure 3 Overall survival and progression-free survival as a function of CXCL12 expression. Plots of Kaplan-Meier estimates for overall
survival (A) and progression-free survival (B) of EOC patients with tumor tissues identified as CXCL12low/moderate (n = 97, solid blue line) or
CXCL12high (n = 86, dotted red line). P values are those obtained in log-rank tests.
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paclitaxel/carboplatin/gemcitabine; TMA: Tissue microarray; VEGF: vascular
endothelium growth factor.
Acknowledgements and Funding
This work was supported by Association pour la Recherche sur le Cancer
(ARC, grant number 4982), by Assistance-Publique Hôpitaux de Paris (AP-HP,
grant number 07018), Université Paris-Sud 11, and by Institut National de la
Santé et de la Recherche Médicale (INSERM). Tumor collection was
supported by GINECO (ARCAGY).
We thank P. Laurent and B. N’Guyen, Service d’Anatomie et de Cytologie
Pathologiques, AP-HP, Université Paris-Sud 11, Hôpital Antoine-Béclère,
Clamart, France, for technical assistance.
Author details
1INSERM UMR_S 996, Université Paris-Sud 11, Clamart, 92140 France. 2JE2492,
Assistance-Publique Hôpitaux de Paris (AP-HP), Université Paris-Sud 11,
Villejuif, 94800 France. 3Cabinet de Pathologie Tolbiac, Paris, 75013 France.
4Service d’Oncologie médicale, AP-HP, Université Paris Descartes, Hôpital
Hôtel-Dieu, Paris, 75001 France. 5Centre Claudius Regaud, Toulouse, 33000
France. 6INSERM U819, Laboratoire de Pathogénie Virale, Institut Pasteur,
Paris, 75015 France. 7Service de Microbiologie-Immunologie Biologique, AP-
HP, Université Paris-Sud 11, Hôpital Antoine-Béclère, Clamart, 92140 France.
8Service d’Anatomie et de Cytologie Pathologiques, AP-HP, Université Paris-
Sud 11, Hôpital Antoine-Béclère, Clamart, 92140 France.
Authors’ contributions
Conceived and designed the experiments: VM, KB. Performed the
experiments: FG, SN, LBD. Analyzed the data: VM, SCB, PB, SP, KB.
Contributed reagents/materials/analysis tools: SCB, SP, EPL, JA, LG, FAS.
Wrote the paper: VM, SCB, PB, KB. Provided funding: DE, KB. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 28 October 2010 Accepted: 16 March 2011
Published: 16 March 2011
References
1. Permuth-Wey J, Sellers TA: Epidemiology of ovarian cancer. Methods Mol
Biol 2009, 472:413-437.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics,
2008. CA Cancer J Clin 2008, 58(2):71-96.
3. Shimizu Y, Kamoi S, Amada S, Akiyama F, Silverberg SG: Toward the
development of a universal grading system for ovarian epithelial
carcinoma: testing of a proposed system in a series of 461 patients with
uniform treatment and follow-up. Cancer 1998, 82(5):893-901.
4. Shih Ie M, Kurman RJ: Ovarian tumorigenesis: a proposed model based
on morphological and molecular genetic analysis. Am J Pathol 2004,
164(5):1511-1518.
5. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ,
Barrett JC, Boyd J, Birrer MJ: Gene expression profiles of serous,
endometrioid, and clear cell subtypes of ovarian and endometrial
cancer. Clin Cancer Res 2005, 11(18):6422-6430.
6. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S,
Bowen NJ, Ionescu DN, Rajput A, et al: Ovarian carcinoma subtypes are
different diseases: implications for biomarker studies. PLoS Med 2008,
5(12):e232.
7. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-
Culver H, Chang-Claude J, Cramer DW, DiCioccio R, et al: A genome-wide
association study identifies a new ovarian cancer susceptibility locus on
9p22.2. Nat Genet 2009, 41(9):996-1000.
8. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM,
Misek DE, Wu R, Zhai Y, Darrah DM, et al: Gene expression in ovarian
cancer reflects both morphology and biological behavior, distinguishing
clear cell from other poor-prognosis ovarian carcinomas. Cancer Res
2002, 62(16):4722-4729.
9. White NM, Mathews M, Yousef GM, Prizada A, Popadiuk C, Dore JJ: KLK6
and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br J
Cancer 2009, 101(7):1107-1113.
10. Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 2004,
4(7):540-550.
11. Barbieri F, Bajetto A, Florio T: Role of chemokine network in the
development and progression of ovarian cancer: a potential novel
pharmacological target. J Oncol 2010, 2010:426956.
12. Lazennec G, Richmond A: Chemokines and chemokine receptors: new
insights into cancer-related inflammation. Trends Mol Med 2010,
16(3):133-144.
13. Wilson J, Balkwill F: The role of cytokines in the epithelial cancer
microenvironment. Semin Cancer Biol 2002, 12(2):113-120.
14. Kryczek I, Wei S, Keller E, Liu R, Zou W: Stromal derived factor (SDF-1/
CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 2007,
292:C987-95.
15. Zou W, Machelon V, Coulomb-L’Hermine A, Borvak J, Nome F, Isaeva T,
Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, et al: Stromal-derived
factor-1 in human tumors recruits and alters the function of
plasmacytoid precursor dendritic cells. Nat Med 2001, 7(12):1339-1346.
16. Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S,
Bridger G, Balkwill FR: Multiple actions of the chemokine CXCL12 on
epithelial tumor cells in human ovarian cancer. Cancer Res 2002,
62(20):5930-5938.
17. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L,
Wei S, Zou L, Machelon V, et al: CXCL12 and vascular endothelial growth
factor synergistically induce neoangiogenesis in human ovarian cancers.
Cancer Res 2005, 65(2):465-472.
18. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR: Epithelial cancer
cell migration: a role for chemokine receptors? Cancer Res 2001,
61(13):4961-4965.
19. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F: Involvement
of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of
epithelial ovarian carcinoma. Int J Cancer 2008, 122(1):91-99.
20. Barbolina MV, Kim M, Liu Y, Shepard J, Belmadani A, Miller RJ, Shea LD,
Stack MS: Microenvironmental regulation of chemokine (C-X-C-motif)
receptor 4 in ovarian carcinoma. Mol Cancer Res 2010, 8(5):653-664.
21. Pils D, Pinter A, Reibenwein J, Alfanz A, Horak P, Schmid BC, Hefler L,
Horvat R, Reinthaller A, Zeillinger R, et al: In ovarian cancer the prognostic
influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling
pathway. Br J Cancer 2007, 96(3):485-491.
22. Jiang YP, Wu XH, Shi B, Wu WX, Yin GR: Expression of chemokine CXCL12
and its receptor CXCR4 in human epithelial ovarian cancer: an
independent prognostic factor for tumor progression. Gynecol Oncol
2006, 103(1):226-233.
23. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC: Ovarian surface
epithelium: biology, endocrinology, and pathology. Endocr Rev 2001,
22(2):255-288.
24. Karst AM, Drapkin R: Ovarian cancer pathogenesis: a model in evolution.
J Oncol 2010, 2010:932371.
25. Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O,
Leduc B, Bain S, Orfeuvre H, Audouin J, Pujade-Lauraine E: HER-2
overexpression is an independent marker of poor prognosis of
advanced primary ovarian carcinoma: a multicenter study of the
GINECO group. Ann Oncol 2004, 15(1):104-112.
26. Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broet P,
Guastalla JP, Allouache D, Combe M, Weber B, Pujade-Lauraine E, et al:
HER2 status in ovarian carcinomas: a multicenter GINECO study of 320
patients. PLoS One 2007, 2(11):e1138.
27. du Bois A, Herrstedt J, Hardy-Bessard AC, Muller HH, Harter P, Kristensen G,
Joly F, Huober J, Avall-Lundqvist E, Weber B, et al: Phase III trial of
carboplatin plus paclitaxel with or without gemcitabine in first-line
treatment of epithelial ovarian cancer. J Clin Oncol 2010, 28:4162-4169.
28. Drapkin R, Crum CP, Hecht JL: Expression of candidate tumor markers in
ovarian carcinoma and benign ovary: evidence for a link between
epithelial phenotype and neoplasia. Hum Pathol 2004, 35(8):1014-1021.
29. Redjimi N, Gaudin F, Touboul C, Emilie D, Pallardy M, Biola-Vidamment A,
Fernandez H, Prevot S, Balabanian K, Machelon V: Identification of
glucocorticoid-induced leucine zipper as a key regulator of tumor cell
proliferation in epithelial ovarian cancer. Mol Cancer 2009, 8:83.
30. Coulomb-L’Hermin A, Amara A, Schiff C, Durand-Gasselin I, Foussat A,
Delaunay T, Chaouat G, Capron F, Ledee N, Galanaud P, et al: Stromal cell-
derived factor 1 (SDF-1) and antenatal human B cell lymphopoiesis:
Machelon et al. BMC Cancer 2011, 11:97
http://www.biomedcentral.com/1471-2407/11/97
Page 9 of 10
expression of SDF-1 by mesothelial cells and biliary ductal plate
epithelial cells. Proc Natl Acad Sci USA 1999, 96(15):8585-8590.
31. Balabanian K, Couderc J, Bouchet-Delbos L, Amara A, Berrebi D, Foussat A,
Baleux F, Portier A, Durand-Gasselin I, Coffman RL, et al: Role of the
chemokine stromal cell-derived factor 1 in autoantibody production and
nephritis in murine lupus. J Immunol 2003, 170(6):3392-3400.
32. Kryczek I, Frydman N, Gaudin F, Krzysiek R, Fanchin R, Emilie D, Chouaib S,
Zou W, Machelon V: The chemokine SDF-1/CXCL12 contributes to T
lymphocyte recruitment in human pre-ovulatory follicles and
coordinates with lymphocytes to increase granulosa cell survival and
embryo quality. Am J Reprod Immunol 2005, 54(5):270-283.
33. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R,
Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in
invasive human breast carcinomas promote tumor growth and
angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005,
121(3):335-348.
34. Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, Kindelberger DW,
Hirsch MS, Crum CP, Marto JA, et al: Primary ex vivo cultures of human
fallopian tube epithelium as a model for serous ovarian carcinogenesis.
Oncogene 2010, 29(8):1103-1113.
35. Naora H, Montell DJ: Ovarian cancer metastasis: integrating insights from
disparate model organisms. Nat Rev Cancer 2005, 5(5):355-366.
36. Wendt MK, Johanesen PA, Kang-Decker N, Binion DG, Shah V, Dwinell MB:
Silencing of epithelial CXCL12 expression by DNA hypermethylation
promotes colonic carcinoma metastasis. Oncogene 2006,
25(36):4986-4997.
37. Zhou W, Jiang Z, Liu N, Xu F, Wen P, Liu Y, Zhong W, Song X, Chang X,
Zhang X, et al: Down-regulation of CXCL12 mRNA expression by
promoter hypermethylation and its association with metastatic
progression in human breast carcinomas. J Cancer Res Clin Oncol 2009,
135(1):91-102.
38. Akishima-Fukasawa Y, Nakanishi Y, Ino Y, Moriya Y, Kanai Y, Hirohashi S:
Prognostic significance of CXCL12 expression in patients with colorectal
carcinoma. Am J Clin Pathol 2009, 132(2):202-210.
39. Liang JJ, Zhu S, Bruggeman R, Zaino R, Evans D, Fleming JB, Gomez HF,
Zander DS, Wang H: High levels of expression of human stromal cell-
derived factor-1 are associated with worse prognosis in patients with
stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers
Prev 2010, 19(10):2598-2604.
40. Hassan S, Ferrario C, Saragovi U, Quenneville L, Gaboury L, Baccarelli A,
Salvucci O, Basik M: The influence of tumor-host interactions in the
stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining
metastatic risk in breast cancer. Am J Pathol 2009, 175(1):66-73.
41. Sasaki K, Natsugoe S, Ishigami S, Matsumoto M, Okumura H, Setoyama T,
Uchikado Y, Kita Y, Tamotsu K, Hanazono K, et al: Expression of CXCL12
and its receptor CXCR4 in esophageal squamous cell carcinoma. Oncol
Rep 2009, 21(1):65-71.
42. Gelmini S, Mangoni M, Castiglione F, Beltrami C, Pieralli A, Andersson KL,
Fambrini M, Taddei GL, Serio M, Orlando C: The CXCR4/CXCL12 axis in
endometrial cancer. Clin Exp Metastasis 2009, 26(3):261-268.
43. Gilbert DC, Chandler I, McIntyre A, Goddard NC, Gabe R, Huddart RA,
Shipley J: Clinical and biological significance of CXCL12 and CXCR4
expression in adult testes and germ cell tumours of adults and
adolescents. J Pathol 2009, 217(1):94-102.
44. Barbero S, Bonavia R, Bajetto A, Porcile C, Pirani P, Ravetti JL, Zona GL,
Spaziante R, Florio T, Schettini G: Stromal cell-derived factor 1 alpha
stimulates human glioblastoma cell growth through the activation of
both extracellular signal-regulated kinases 1/2 and Akt. Cancer Res 2003,
63(8):1969-1974.
45. Lis R, Touboul C, Mirshahi P, Ali F, Mathew S, Nolan DJ, Maleki TM,
Abdalla SA, Raynaud CM, Querleu D, et al: Tumor associated mesenchymal
stem cells protects ovarian cancer cells from hyperthermia through
CXCL12. Int J Cancer 2010, 128:715-725.
46. Laguri C, Arenzana-Seisdedos F, Lortat-Jacob H: Relationships between
glycosaminoglycan and receptor binding sites in chemokines-the
CXCL12 example. Carbohydr Res 2008, 343(12):2018-2023.
47. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B,
Arenzana-Seisdedos F, Thelen M, Bachelerie F: The chemokine SDF-1/
CXCL12 binds to and signals through the orphan receptor RDC1 in T
lymphocytes. J Biol Chem 2005, 280(42):35760-35766.
48. Thelen M, Thelen S: CXCR7, CXCR4 and CXCL12: an eccentric trio ? J
Neuroimmunol 2008, 198(1-2):9-13.
49. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z,
Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, et al: A novel chemokine
receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and
tumor development. J Exp Med 2006, 203(9):2201-2213.
50. Mirisola V, Zuccarino A, Bachmeier BE, Sormani MP, Falter J, Nerlich A,
Pfeffer U: CXCL12/SDF1 expression by breast cancers is an independent
prognostic marker of disease-free and overall survival. Eur J Cancer 2009,
45(14):2579-2587.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/97/prepub
doi:10.1186/1471-2407-11-97
Cite this article as: Machelon et al.: CXCL12 expression by healthy and
malignant ovarian epithelial cells. BMC Cancer 2011 11:97.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Machelon et al. BMC Cancer 2011, 11:97
http://www.biomedcentral.com/1471-2407/11/97
Page 10 of 10
